BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colomer Gould VF, Goti D, Pearce D, Gonzalez GA, Gao H, Bermudez de Leon M, Jenkins NA, Copeland NG, Ross CA, Brown DR. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol Dis 2007;27:362-9. [PMID: 17632007 DOI: 10.1016/j.nbd.2007.06.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Costa Mdo C, Paulson HL. Toward understanding Machado-Joseph disease. Prog Neurobiol 2012;97:239-57. [PMID: 22133674 DOI: 10.1016/j.pneurobio.2011.11.006] [Cited by in Crossref: 158] [Cited by in F6Publishing: 152] [Article Influence: 14.4] [Reference Citation Analysis]
2 Takahashi T, Katada S, Onodera O. Polyglutamine diseases: where does toxicity come from? what is toxicity? where are we going? J Mol Cell Biol 2010;2:180-91. [PMID: 20410236 DOI: 10.1093/jmcb/mjq005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 8.6] [Reference Citation Analysis]
3 Esteves S, Duarte-Silva S, Maciel P. Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts. Med Res Rev 2017;37:860-906. [PMID: 27870126 DOI: 10.1002/med.21425] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
4 Simoes AT, Goncalves N, Koeppen A, Deglon N, Kugler S, Duarte CB, Pereira de Almeida L. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 2012;135:2428-39. [DOI: 10.1093/brain/aws177] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
5 Jadhav S, Zilka N, Novak M. Protein truncation as a common denominator of human neurodegenerative foldopathies. Mol Neurobiol 2013;48:516-32. [PMID: 23516100 DOI: 10.1007/s12035-013-8440-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
6 He L, Wang S, Peng L, Zhao H, Li S, Han X, Habimana JD, Chen Z, Wang C, Peng Y, Peng H, Xie Y, Lei L, Deng Q, Wan L, Wan N, Yuan H, Gong Y, Zou G, Li Z, Tang B, Jiang H. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells. Transl Psychiatry 2021;11:479. [PMID: 34535635 DOI: 10.1038/s41398-021-01605-2] [Reference Citation Analysis]
7 Nicastro G, Todi SV, Karaca E, Bonvin AM, Paulson HL, Pastore A. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One 2010;5:e12430. [PMID: 20865150 DOI: 10.1371/journal.pone.0012430] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
8 Watson LM, Wood MJ. RNA therapy for polyglutamine neurodegenerative diseases. Expert Rev Mol Med 2012;14:e3. [PMID: 22293529 DOI: 10.1017/erm.2011.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
9 Teixeira-Castro A, Ailion M, Jalles A, Brignull HR, Vilaça JL, Dias N, Rodrigues P, Oliveira JF, Neves-Carvalho A, Morimoto RI, Maciel P. Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways. Hum Mol Genet 2011;20:2996-3009. [PMID: 21546381 DOI: 10.1093/hmg/ddr203] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
10 Evers MM, Tran HD, Zalachoras I, Pepers BA, Meijer OC, den Dunnen JT, van Ommen GJ, Aartsma-Rus A, van Roon-Mom WM. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis 2013;58:49-56. [PMID: 23659897 DOI: 10.1016/j.nbd.2013.04.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
11 Pozzi C, Valtorta M, Tedeschi G, Galbusera E, Pastori V, Bigi A, Nonnis S, Grassi E, Fusi P. Study of subcellular localization and proteolysis of ataxin-3. Neurobiol Dis 2008;30:190-200. [PMID: 18353661 DOI: 10.1016/j.nbd.2008.01.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
12 Blum ES, Schwendeman AR, Shaham S. PolyQ disease: misfiring of a developmental cell death program? Trends Cell Biol 2013;23:168-74. [PMID: 23228508 DOI: 10.1016/j.tcb.2012.11.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
13 Evers MM, Toonen LJ, van Roon-Mom WM. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies. Mol Neurobiol 2014;49:1513-31. [PMID: 24293103 DOI: 10.1007/s12035-013-8596-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
14 Kuiper EF, de Mattos EP, Jardim LB, Kampinga HH, Bergink S. Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch. Front Neurosci 2017;11:145. [PMID: 28386214 DOI: 10.3389/fnins.2017.00145] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
15 Young JE, Garden GA, Martinez RA, Tanaka F, Sandoval CM, Smith AC, Sopher BL, Lin A, Fischbeck KH, Ellerby LM, Morrison RS, Taylor JP, La Spada AR. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. J Neurosci 2009;29:1987-97. [PMID: 19228953 DOI: 10.1523/JNEUROSCI.4072-08.2009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
16 Pennuto M, Palazzolo I, Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum Mol Genet 2009;18:R40-7. [PMID: 19297400 DOI: 10.1093/hmg/ddn412] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
17 Nóbrega C, Simões AT, Duarte-Neves J, Duarte S, Vasconcelos-Ferreira A, Cunha-Santos J, Pereira D, Santana M, Cavadas C, de Almeida LP. Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis. Adv Exp Med Biol 2018;1049:349-67. [PMID: 29427113 DOI: 10.1007/978-3-319-71779-1_18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Moore LR, Keller L, Bushart DD, Delatorre RG, Li D, McLoughlin HS, do Carmo Costa M, Shakkottai VG, Smith GD, Paulson HL. Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line. Stem Cell Res 2019;39:101504. [PMID: 31374463 DOI: 10.1016/j.scr.2019.101504] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. Neuroscientist 2011;17:475-92. [PMID: 21311053 DOI: 10.1177/1073858410390378] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 10.2] [Reference Citation Analysis]
20 Figiel M, Szlachcic WJ, Switonski PM, Gabka A, Krzyzosiak WJ. Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol 2012;46:393-429. [PMID: 22956270 DOI: 10.1007/s12035-012-8315-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
21 Ingram MA, Orr HT, Clark HB. Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias. Brain Res Bull 2012;88:33-42. [PMID: 21810454 DOI: 10.1016/j.brainresbull.2011.07.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
22 Silva A, de Almeida AV, Macedo-Ribeiro S. Polyglutamine expansion diseases: More than simple repeats. J Struct Biol 2018;201:139-54. [PMID: 28928079 DOI: 10.1016/j.jsb.2017.09.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
23 Rajamani K, Liu JW, Wu CH, Chiang IT, You DH, Lin SY, Hsieh DK, Lin SZ, Harn HJ, Chiou TW. n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3. Neuropharmacology 2017;117:434-46. [PMID: 28223212 DOI: 10.1016/j.neuropharm.2017.02.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
24 Stoyas CA, La Spada AR. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. Handb Clin Neurol 2018;147:143-70. [PMID: 29325609 DOI: 10.1016/B978-0-444-63233-3.00011-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
25 Weber JJ, Golla M, Guaitoli G, Wanichawan P, Hayer SN, Hauser S, Krahl A, Nagel M, Samer S, Aronica E, Carlson CR, Schöls L, Riess O, Gloeckner CJ, Nguyen HP, Hübener-schmid J. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. Brain 2017;140:1280-99. [DOI: 10.1093/brain/awx039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
26 Weber JJ, Sowa AS, Binder T, Hübener J. From pathways to targets: understanding the mechanisms behind polyglutamine disease. Biomed Res Int 2014;2014:701758. [PMID: 25309920 DOI: 10.1155/2014/701758] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
27 Hübener J, Vauti F, Funke C, Wolburg H, Ye Y, Schmidt T, Wolburg-Buchholz K, Schmitt I, Gardyan A, Driessen S, Arnold HH, Nguyen HP, Riess O. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. Brain 2011;134:1925-42. [PMID: 21653538 DOI: 10.1093/brain/awr118] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
28 Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 2009;110:1737-65. [PMID: 19650870 DOI: 10.1111/j.1471-4159.2009.06302.x] [Cited by in Crossref: 136] [Cited by in F6Publishing: 123] [Article Influence: 10.5] [Reference Citation Analysis]
29 Antony PMA, Mäntele S, Mollenkopf P, Boy J, Kehlenbach RH, Riess O, Schmidt T. Identification and functional dissection of localization signals within ataxin-3. Neurobiology of Disease 2009;36:280-92. [DOI: 10.1016/j.nbd.2009.07.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
30 Lee JH, Lin SY, Liu JW, Lin SZ, Harn HJ, Chiou TW. n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway. Int J Mol Sci 2021;22:6339. [PMID: 34199295 DOI: 10.3390/ijms22126339] [Reference Citation Analysis]
31 Watchon M, Yuan KC, Mackovski N, Svahn AJ, Cole NJ, Goldsbury C, Rinkwitz S, Becker TS, Nicholson GA, Laird AS. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy. J Neurosci 2017;37:7782-94. [PMID: 28687604 DOI: 10.1523/JNEUROSCI.1142-17.2017] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 7.4] [Reference Citation Analysis]
32 Magaña JJ, Velázquez-Pérez L, Cisneros B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol 2013;47:90-104. [PMID: 22996397 DOI: 10.1007/s12035-012-8348-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
33 Matos CA, de Almeida LP, Nóbrega C. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J Neurochem 2019;148:8-28. [PMID: 29959858 DOI: 10.1111/jnc.14541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
34 Dansithong W, Paul S, Figueroa KP, Rinehart MD, Wiest S, Pflieger LT, Scoles DR, Pulst SM. Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet 2015;11:e1005182. [PMID: 25902068 DOI: 10.1371/journal.pgen.1005182] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
35 Matos CA, de Macedo-ribeiro S, Carvalho AL. Polyglutamine diseases: The special case of ataxin-3 and Machado–Joseph disease. Progress in Neurobiology 2011;95:26-48. [DOI: 10.1016/j.pneurobio.2011.06.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 8.4] [Reference Citation Analysis]
36 Christie NT, Lee AL, Fay HG, Gray AA, Kikis EA. Novel polyglutamine model uncouples proteotoxicity from aging. PLoS One 2014;9:e96835. [PMID: 24817148 DOI: 10.1371/journal.pone.0096835] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
37 Schmidt J, Schmidt T. Animal Models of Machado-Joseph Disease. Adv Exp Med Biol 2018;1049:289-308. [PMID: 29427110 DOI: 10.1007/978-3-319-71779-1_15] [Reference Citation Analysis]
38 Colomer Gould VF. Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 2012;9:285-96. [PMID: 22451301 DOI: 10.1007/s13311-012-0117-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
39 Jung J, Xu K, Lessing D, Bonini NM. Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 2009;18:4843-52. [PMID: 19783548 DOI: 10.1093/hmg/ddp456] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]